Join Growin Stock Community!

Axogen, inc.AXGN.US Overview

US StockHealthcare
(No presentation for AXGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AXGN AI Insights

AXGN Overall Performance

AXGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AXGN Recent Performance

-3.37%

Axogen, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AXGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AXGN Key Information

AXGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AXGN Profile

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Price of AXGN

AXGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AXGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.31
PE Ratio (TTM)
-
Forward PE
54.09
PS Ratio (TTM)
7.07
PB Ratio
13.26
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.31%
Net Margin
-6.97%
Revenue Growth (YoY)
20.21%
Profit Growth (YoY)
17.87%
3-Year Revenue Growth
18.32%
3-Year Profit Growth
13.94%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.31
PE Ratio (TTM)
-
Forward PE
54.09
PS Ratio (TTM)
7.07
PB Ratio
13.26
Price-to-FCF
-
Gross Margin
74.31%
Net Margin
-6.97%
Revenue Growth (YoY)
20.21%
Profit Growth (YoY)
17.87%
3-Year Revenue Growth
18.32%
3-Year Profit Growth
13.94%

  • When is AXGN's latest earnings report released?

    The most recent financial report for Axogen, inc. (AXGN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AXGN's short-term business performance and financial health. For the latest updates on AXGN's earnings releases, visit this page regularly.

  • What is the operating profit of AXGN?

    According to the latest financial report, Axogen, inc. (AXGN) reported an Operating Profit of -9.77M with an Operating Margin of -16.31% this period, representing a decline of 584.48% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AXGN's revenue growth?

    In the latest financial report, Axogen, inc. (AXGN) announced revenue of 59.9M, with a Year-Over-Year growth rate of 21.25%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AXGN have?

    As of the end of the reporting period, Axogen, inc. (AXGN) had total debt of 71.52M, with a debt ratio of 0.32. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AXGN have?

    At the end of the period, Axogen, inc. (AXGN) held Total Cash and Cash Equivalents of 39.55M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AXGN go with three margins increasing?

    In the latest report, Axogen, inc. (AXGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 74.1%%, operating margin of -16.31%%, and net margin of -22%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AXGN's profit trajectory and future growth potential.

  • Is AXGN's EPS continuing to grow?

    According to the past four quarterly reports, Axogen, inc. (AXGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AXGN?

    Axogen, inc. (AXGN)'s Free Cash Flow (FCF) for the period is 1.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 77.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AXGN?

    The latest valuation data shows Axogen, inc. (AXGN) has a Price-To-Earnings (PE) ratio of -107.41 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.